Hansoh Pharmaceutical Group Company Limited
3692
주식 순위
#947
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
주가
$4.29
시가총액
$26.03B
변동 (1일)
5.73%
변동 (1년)
-8.43%
국가
CN
거래 Hansoh Pharmaceutical Group Company Limited (3692)
카테고리
Healthcare
Hansoh Pharmaceutical Group Company Limited (3692)의 EPS
June 2026 기준 EPS TTM: $0.16
Hansoh Pharmaceutical Group Company Limited의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $0.16입니다. 2023년 말에는 회사의 EPS가 $0.07였으며, 이는 2022년의 EPS $0.06와 증가입니다.
Hansoh Pharmaceutical Group Company Limited의 EPS 기록 (2016 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $0.16 | 59.40% |
| 2024 | $0.10 | 43.63% |
| 2023 | $0.07 | 10.66% |
| 2022 | $0.06 | -11.88% |
| 2021 | $0.07 | 7.42% |
| 2020 | $0.07 | -0.15% |
| 2019 | $0.07 | 40.63% |
| 2018 | $0.05 | 11.63% |
| 2017 | $0.04 | 14.97% |
| 2016 | $0.04 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 249.00% |
IN
|
